A 68Ga-labled variant of a trastuzumab-derived DOTA-conjugated F(ab’)2 has been reported for preclinical and clinical imaging of HER2-positive breast cancer 3 h pi [37,38]. This evidence concerns the gene ERBB2 and breast cancer.